Melanie Marklin

Otfried Müller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: August 18, 2026

Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer.

Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer.

Journal: Frontiers in immunology

Published: May 07, 2025

Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

Journal: ImmunoTargets and therapy

Published: April 17, 2025

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.

Journal: Journal of translational medicine

Published: March 27, 2025

FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.

FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.

Journal: Cancer research

Published: January 27, 2025

Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.

Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.

Journal: Cancers

Published: June 05, 2024

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.

Journal: International journal of molecular sciences

Published: March 08, 2024

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

Journal: Science translational medicine

Published: March 06, 2024

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.

Journal: Blood cancer journal

Published: February 26, 2024

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.

Journal: Frontiers in immunology

Published: February 26, 2024

Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts.

Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts.

Journal: Cancers

Published: February 19, 2024

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

Journal: Journal for immunotherapy of cancer

Published: December 21, 2023

Showing 1-12 of 56

Last Updated: 09/26/2026